Product Information
LEVOXYL 88 MCG TABLET is a brand product labeled by Pfizer Inc., priced at $0.9593 per EA under NDC 60793085301. Its NADAC has been published 650 times since Apr 23, 2014.
FDA first approved this application on May 25, 2001. Its Orange Book therapeutic-equivalence code is AB1,AB3 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
88 ug/1
Manufacturer
Pfizer Inc.NDC
60793085301
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVOTHYROXINE SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA021301FDA Approved
5/25/2001
TE Code
AB1,AB3
On Market Since
5/25/2001
Pharmacological Classes
Price Statistics
The NADAC for LEVOXYL 88 MCG TABLET has been published 650 times since Apr 23, 2014, and over the history we have for it it has risen 127.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9593 per EA |
|---|---|
| All-time high | $0.9605 (May 13, 2026) |
| All-time low | $0.4211 (Apr 23, 2014) |
| 52-week high | $0.9605 |
| 52-week low | $0.9144 |
| Median price | $0.8600 |
| Average price | $0.7898 |
| Largest weekly change | +12.5% (Apr 20, 2016) |
| Weeks tracked | 650 |
| Tracking since | Apr 23, 2014 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 95% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Pfizer Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
levothyroxine sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
l-Thyroxine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEVOXYL 88 MCG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LEVOXYL 88 MCG TABLET, manufactured by Pfizer Inc., is $0.9593 per EA (NDC 60793085301), effective Sep 30, 2026.
How has the price of LEVOXYL 88 MCG TABLET changed over time?
Over the history we have for it, the NADAC for LEVOXYL 88 MCG TABLET has risen 127.8%. It has been tracked across 650 weekly CMS publications since Apr 23, 2014.
What are the highest and lowest recorded NADAC prices for LEVOXYL 88 MCG TABLET?
Since Apr 23, 2014, the NADAC for LEVOXYL 88 MCG TABLET has ranged from a low of $0.4211 (Apr 23, 2014) to a high of $0.9605 (May 13, 2026), with a median of $0.8600 per EA.
Are there cheaper alternatives to LEVOXYL 88 MCG TABLET?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LEVOTHYROXINE 88 MCG TABLET, is $0.0495 per EA — about 95% below LEVOXYL 88 MCG TABLET.
Who manufactures LEVOXYL 88 MCG TABLET?
LEVOXYL 88 MCG TABLET (NDC 60793085301) is labeled by Pfizer Inc., and CMS classifies it as a brand product.